CytRx initiates aldoxorubicin Phase 2 trial in HIV-infected patients with Kaposi’s sarcoma

CytRx Corporation, a biopharmaceutical research and development company specializing in oncology, today announced it has initiated a Phase 2 clinical trial to determine preliminary efficacy and safety of aldoxorubicin for HIV-infected patients with Kaposi’s sarcoma.

Read More:
CytRx initiates aldoxorubicin Phase 2 trial in HIV-infected patients with Kaposi’s sarcoma

Share and Enjoy:
  • Print
  • Digg
  • StumbleUpon
  • Facebook
  • Yahoo! Buzz
  • Twitter
  • Google Bookmarks
  • Add to favorites
  • email
  • LinkedIn
  • RSS
  • Tumblr
Share